Alexion Set To Buy Clinical-Stage Pharma Biz In $930M Deal
Alexion Pharmaceuticals said Wednesday it will deepen its rare disease treatment offerings through a $930 million deal for Skadden-led clinical-stage pharmaceuticals company Achillion, a total that could rise should the company's...To view the full article, register now.
Already a subscriber? Click here to view full article